The role of mammography screening attendance and detection mode in predicting breast cancer survival-Is there added prognostic value?

Cancer Epidemiology

Volumn 35, Issue 6, 2011, Pages 545-550

  Biesheuvel, Cornelis ^a,b   Czene, Kamila ^a   Orgeás, Chantal C ^a   Hall, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Breast cancer; Mammography screening.; Prognosis; Survival

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SWEDEN; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAMMOGRAPHY; MIDDLE AGED; PROGNOSIS;

EID: 81055156369     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.02.008     Document Type: Article

References (29)

1. Nystrom L., Andersson I., Bjurstam N., Frisell J., Nordenskjold B., Rutqvist L.E. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919.
2. Tabar L., Yen M.F., Vitak B., Chen H.H., Smith R.A., Duffy S.W. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003, 361:1405-1410.
3. Shapiro S., Venet W., Strax P., Venet L., Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982, 69:349-355.
4. IARC Handbook of Cancer Preventioned 2002, vol. 7. IARC Press, Lyon.
5. SOSEG Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006, 15:45-51.
6. Ernst M.F., Voogd A.C., Coebergh J.W., Roukema J.A. Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening. Cancer 2004, 100:1337-1344.
7. Paci E., Ponti A., Zappa M., Patriarca S., Falini P., Delmastro G., et al. Early diagnosis, not differential treatment, explains better survival in service screening. Eur J Cancer 2005, 41:2728-2734.
8. Gill P.G., Farshid G., Luke C.G., Roder D.M. Detection by screening mammography is a powerful independent predictor of survival in women diagnosed with breast cancer. Breast 2004, 13:15-22.
9. Dong W., Berry D.A., Bevers T.B., Kau S.W., Hsu L., Theriault R.L., et al. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 2008, 17:1096-1103.
10. Shen Y., Yang Y., Inoue L.Y., Munsell M.F., Miller A.B., Berry D.A. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203.
11. Wishart G.C., Greenberg D.C., Britton P.D., Chou P., Brown C.H., Purushotham A.D., et al. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer 2008, 98:1741-1744.
12. Fletcher A.S., Erbas B., Kavanagh A.M., Hart S., Rodger A., Gertig D.M. Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis. Breast 2005, 14:192-200.
13. Jernstrom H., Frenander J., Ferno M., Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999, 80:1453-1458.
14. Rosenberg L.U., Granath F., Dickman P.W., Einarsdottir K., Wedren S., Persson I., et al. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 2008, 10:R78.
15. Schairer C., Gail M., Byrne C., Rosenberg P.S., Sturgeon S.R., Brinton L.A., et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999, 91:264-270.
16. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253.
17. Olsson S., Andersson I., Karlberg I., Bjurstam N., Frodis E., Hakansson S. Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme. J Med Screen 2000, 7:14-18.
18. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
19. Nystrom L., Larsson L.G., Rutqvist L.E., Lindgren A., Lindqvist M., Ryden S., et al. Determination of cause of death among breast cancer cases in the Swedish randomized mammography screening trials. A comparison between official statistics and validation by an endpoint committee. Acta Oncol 1995, 34:145-152.
20. Brekelmans C.T., Peeters P.H., Deurenberg J.J., Collette H.J. Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 1995, 31A:1830-1835.
21. Holmberg L.H., Tabar L., Adami H.O., Bergstrom R. Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 1986, 2:27-30.
22. Porter G.J., Evans A.J., Burrell H.C., Lee A.H., Ellis I.O., Chakrabarti J. Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 2006, 13:115-122.
23. Zackrisson S., Janzon L., Manjer J., Andersson I. Improved survival rate for women with interval breast cancer - results from the breast cancer screening programme in Malmo Sweden 1976-1999. J Med Screen 2007, 14:138-143.
24. Andersson I., Aspegren K., Janzon L., Landberg T., Lindholm K., Linell F., et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988, 297:943-948.
25. Bordas P., Jonsson H., Nystrom L., Lenner P. Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast 2007, 16:47-54.
26. Frisell J., von Rosen A., Wiege M., Nilsson B., Goldman S. Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992, 24:11-16.
27. Boer R., Warmerdam P., de Koning H., van Oortmarssen G. Extra incidence caused by mammographic screening. Lancet 1994, 343:979.
28. Chen J.S., Prorok P.C. Lead time estimation in a controlled screening program. Am J Epidemiol 1983, 118:740-751.
29. Duffy S.W.C.J., Tabar L., Vitak B., Hsiu-Hsi Chen T., Yen M.-F., Smith R.A. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Statist 2002, 51:235-243.